Brian P Fallon1, Orsolya Lautner-Csorba2, Alex J Thompson2, Gergely Lautner2, Adrianna Kayden2, Matthew D Johnson2, Stephen L Harvey2, Mark W Langley2, Alvaro Rojas Peña2, Robert H Bartlett2, Ronald B Hirschl3. 1. Extracorporeal Life Support Laboratory, Department of Surgery, Michigan Medicine, B560 MSRB II/SPC 5686, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA. Electronic address: bfallon@med.umich.edu. 2. Extracorporeal Life Support Laboratory, Department of Surgery, Michigan Medicine, B560 MSRB II/SPC 5686, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA. 3. Extracorporeal Life Support Laboratory, Department of Surgery, Michigan Medicine, B560 MSRB II/SPC 5686, 1150 W. Medical Center Drive, Ann Arbor, MI 48109, USA; Department of Surgery, Section of Pediatric Surgery, Michigan Medicine, Ann Arbor, MI, USA.
Abstract
BACKGROUND: Artificial lungs have the potential to serve as a bridge to transplantation or recovery for children with end-stage lung disease dependent on extracorporeal life support, but such devices currently require systemic anticoagulation. We describe our experience using the novel Nitric Oxide (NO) Surface Anticoagulation (NOSA) system-an NO-releasing circuit with NO in the sweep gas-with the Pediatric MLung-a low-resistance, pumpless artificial lung. METHODS: NO flux testing: MLungs (n = 4) were tested using veno-venous extracorporeal life support in a sheep under anesthesia with blood flow set to 0.5 and 1 L/min and sweep gas blended with 100 ppm NO at 1, 2, and 4 L/min. NO and NO2 were measured in the sweep and exhaust gas to calculate NO flux across the MLung membrane. Pumpless implants: Sheep (20-100 kg, n = 3) underwent thoracotomy and cannulation via the pulmonary artery (device inflow) and left atrium (device outflow) using cannulae and circuit components coated with an NO donor (diazeniumdiolated dibutylhexanediamine; DBHD-N2O2) and argatroban. Animals were connected to the MLung with 100 ppm NO in the sweep gas under anesthesia for 24 h with no systemic anticoagulation after cannulation. RESULTS: NO flux testing: NO flux averaged 3.4 ± 1.0 flux units (x10-10 mol/cm2/min) (human vascular endothelium: 0.5-4 flux units). Pumpless implants: 3 sheep survived 24 h with patent circuits. MLung blood flow was 716 ± 227 mL/min. Outlet oxygen saturation was 98.3 ± 2.6%. Activated clotting time was 151±24 s. Platelet count declined from 334,333 ± 112,225 to 123,667 ± 7,637 over 24 h. Plasma free hemoglobin and leukocyte and platelet activation did not significantly change. CONCLUSIONS: The NOSA system provides NO flux across a gas-exchange membrane of a pumpless artificial lung at a similar rate as native vascular endothelium and achieves effective local anticoagulation of an artificial lung circuit for 24 h.
BACKGROUND: Artificial lungs have the potential to serve as a bridge to transplantation or recovery for children with end-stage lung disease dependent on extracorporeal life support, but such devices currently require systemic anticoagulation. We describe our experience using the novel Nitric Oxide (NO) Surface Anticoagulation (NOSA) system-an NO-releasing circuit with NO in the sweep gas-with the Pediatric MLung-a low-resistance, pumpless artificial lung. METHODS: NO flux testing: MLungs (n = 4) were tested using veno-venous extracorporeal life support in a sheep under anesthesia with blood flow set to 0.5 and 1 L/min and sweep gas blended with 100 ppm NO at 1, 2, and 4 L/min. NO and NO2 were measured in the sweep and exhaust gas to calculate NO flux across the MLung membrane. Pumpless implants: Sheep (20-100 kg, n = 3) underwent thoracotomy and cannulation via the pulmonary artery (device inflow) and left atrium (device outflow) using cannulae and circuit components coated with an NO donor (diazeniumdiolated dibutylhexanediamine; DBHD-N2O2) and argatroban. Animals were connected to the MLung with 100 ppm NO in the sweep gas under anesthesia for 24 h with no systemic anticoagulation after cannulation. RESULTS: NO flux testing: NO flux averaged 3.4 ± 1.0 flux units (x10-10 mol/cm2/min) (human vascular endothelium: 0.5-4 flux units). Pumpless implants: 3 sheep survived 24 h with patent circuits. MLung blood flow was 716 ± 227 mL/min. Outlet oxygen saturation was 98.3 ± 2.6%. Activated clotting time was 151±24 s. Platelet count declined from 334,333 ± 112,225 to 123,667 ± 7,637 over 24 h. Plasma free hemoglobin and leukocyte and platelet activation did not significantly change. CONCLUSIONS: The NOSA system provides NO flux across a gas-exchange membrane of a pumpless artificial lung at a similar rate as native vascular endothelium and achieves effective local anticoagulation of an artificial lung circuit for 24 h.
Authors: Thomas V Brogan; Luke Zabrocki; Ravi R Thiagarajan; Peter T Rycus; Susan L Bratton Journal: Pediatr Crit Care Med Date: 2012-07 Impact factor: 3.624
Authors: Rei Ukita; Kan Wu; Xiaojie Lin; Neil M Carleton; Noritsugu Naito; Angela Lai; Chi Chi Do-Nguyen; Caitlin T Demarest; Shaoyi Jiang; Keith E Cook Journal: Acta Biomater Date: 2019-05-10 Impact factor: 8.947
Authors: Timothy S Lancaster; Jacob R Miller; Deirdre J Epstein; Nicholas C DuPont; Stuart C Sweet; Pirooz Eghtesady Journal: J Heart Lung Transplant Date: 2016-10-17 Impact factor: 10.247
Authors: Kristen Nelson-McMillan; Luca A Vricella; Fray Dylan Stewart; John Young; Ashish S Shah; Narutoshi Hibino; John D Coulson Journal: ASAIO J Date: 2020-01 Impact factor: 2.872
Authors: Avery C Rossidis; Kendall M Lawrence; Ali Y Mejaddam; Aimee G Kim; Heron D Baumgarten; Barbara E Coons; Kathleen Young; Stylianos Monos; Grace Hwang; Alan W Flake; Marcus G Davey Journal: ASAIO J Date: 2020-06 Impact factor: 2.872
Authors: David M Hoganson; Avihu Z Gazit; Umar S Boston; Stuart C Sweet; R Mark Grady; Charles B Huddleston; Pirooz Eghtesady Journal: J Thorac Cardiovasc Surg Date: 2013-11-04 Impact factor: 5.209
Authors: Terry C Major; David O Brant; Melissa M Reynolds; Robert H Bartlett; Mark E Meyerhoff; Hitesh Handa; Gail M Annich Journal: Biomaterials Date: 2009-12-29 Impact factor: 12.479
Authors: Shannon M Fernando; Danial Qureshi; Peter Tanuseputro; Sonny Dhanani; Anne-Marie Guerguerian; Sam D Shemie; Robert Talarico; Eddy Fan; Laveena Munshi; Bram Rochwerg; Damon C Scales; Daniel Brodie; Kednapa Thavorn; Kwadwo Kyeremanteng Journal: Crit Care Date: 2020-04-06 Impact factor: 9.097